Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02809768 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02809768 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 48 participants.
The verdict
NCT02809768, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of concomitant administration with fluconazole, itraconazole, and rifampin on the pharmacokinetics (PK) of a single 20-mg dose of avatrombopag in healthy participants.
Interventions
- DRUG Fluconazole
- DRUG Rifampin
- DRUG Itraconazole
- DRUG Avatrombopag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02809768
The ClinicalTrials.gov registry entry for NCT02809768 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fluconazole is the first listed.
NCT02809768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02809768 about?
NCT02809768 is a clinical study titled "Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects". The purpose of this study is to determine the effects of concomitant administration with fluconazole, itraconazole, and rifampin on the pharmacokinetics (PK) of a single 20-mg dose of avatrombopag in healthy participants.
What is the current status of trial NCT02809768?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2016-04. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02809768?
The interventions under investigation include: Fluconazole (DRUG), Rifampin (DRUG), Itraconazole (DRUG), Avatrombopag (DRUG).
Who is sponsoring clinical trial NCT02809768?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.